Role of angiogenesis in adenomyosis-associated abnormal uterine bleeding and subfertility: a systematic review.
abnormal uterine bleeding
adenomyosis
angiogenesis
anti-angiogenic therapy
endometriosis
subfertility
Journal
Human reproduction update
ISSN: 1460-2369
Titre abrégé: Hum Reprod Update
Pays: England
ID NLM: 9507614
Informations de publication
Date de publication:
11 09 2019
11 09 2019
Historique:
received:
11
02
2019
revised:
11
06
2019
accepted:
19
06
2019
pubmed:
11
9
2019
medline:
23
5
2020
entrez:
11
9
2019
Statut:
ppublish
Résumé
Adenomyosis commonly occurs with abnormal uterine bleeding (AUB) and is associated with subfertility and a higher miscarriage rate. Recent evidence showed abnormal vascularization in the endometrium in patients with adenomyosis, suggesting a role of angiogenesis in the pathophysiology of AUB and subfertility in adenomyosis and providing a possible treatment target. We hypothesized that the level of abnormal vascularization and expression of angiogenic markers is increased in the ectopic and eutopic endometrium of adenomyosis patients in comparison with the endometrium of control patients. This was investigated through a search of the literature. A systematic search was performed in PubMed and Embase until February 2019. Combinations of terms for angiogenesis and adenomyosis were applied as well as AUB, subfertility or anti-angiogenic therapy. The main search was limited to clinical studies carried out on premenopausal women. Original research articles focusing on markers of angiogenesis in the endometrium of patients with adenomyosis were included. Studies in which no comparison was made to control patients or which were not published in a peer-reviewed journal were excluded. A second search was performed to explore the therapeutic potential of targeting angiogenesis in adenomyosis. This search also included preclinical studies. A total of 20 articles out of 1669 hits met our selection criteria. The mean vascular density (MVD) was studied by quantification of CD31, CD34, von Willebrand Factor (vWF) or factor-VIII-antibody-stained microvessels in seven studies. All these studies reported a significantly increased MVD in ectopic endometrium, and out of the six articles that took it into account, four studies reported a significantly increased MVD in eutopic endometrium compared with control endometrium. Five articles showed a significantly higher vascular endothelial growth factor expression in ectopic endometrium and three articles in eutopic endometrium compared with control endometrium. The vascular and pro-angiogenic markers α-smooth muscle actin, endoglin, S100A13, vimentin, matrix metalloproteinases (MMPs), nuclear factor (NF)-kB, tissue factor (TF), DJ-1, phosphorylated mammalian target of rapamycin, activin A, folli- and myostatin, CD41, SLIT, roundabout 1 (ROBO1), cyclooxygenase-2, lysophosphatidic acid (LPA) 1,4-5, phospho signal transducer and activator of transcription 3 (pSTAT3), interleukin (IL)-6, IL-22 and transforming growth factor-β1 were increased in ectopic endometrium, and the markers S100A13, MMP-2 and -9, TF, follistatin, myostatin, ROBO1, LPA1 and 4-5, pSTAT3, IL-6 and IL-22 were increased in eutopic endometrium, compared with control endometrium. The anti-angiogenic markers E-cadherin, eukaryotic translation initiation factor 3 subunit and gene associated with retinoic-interferon-induced mortality 19 were decreased in ectopic endometrium and IL-10 in eutopic endometrium, compared with control endometrium. The staining level of vWF and two pro-angiogenic markers (NF-κB nuclear p65 and TF) correlated with AUB in patients with adenomyosis. We found no studies that investigated the possible relationship between markers of angiogenesis and subfertility in adenomyosis patients. Nine articles reported on direct or indirect targeting of angiogenesis in adenomyosis-either by testing hormonal therapy or herbal compounds in clinical studies or by testing angiogenesis inhibitors in preclinical studies. However, there are no clinical studies on the effectiveness of such therapy for adenomyosis-related AUB or subfertility. The results are in agreement with our hypothesis that increased angiogenesis is present in the endometrium of patients with adenomyosis compared with the endometrium of control patients. It is likely that increased angiogenesis leads to fragile and more permeable vessels resulting in adenomyosis-related AUB and possibly subfertility. While this association has not sufficiently been studied yet, our results encourage future studies to investigate the exact role of angiogenesis in the etiology of adenomyosis and related AUB or subfertility in women with adenomyosis in order to design curative or preventive therapeutic strategies.
Sections du résumé
BACKGROUND
Adenomyosis commonly occurs with abnormal uterine bleeding (AUB) and is associated with subfertility and a higher miscarriage rate. Recent evidence showed abnormal vascularization in the endometrium in patients with adenomyosis, suggesting a role of angiogenesis in the pathophysiology of AUB and subfertility in adenomyosis and providing a possible treatment target.
OBJECTIVE AND RATIONALE
We hypothesized that the level of abnormal vascularization and expression of angiogenic markers is increased in the ectopic and eutopic endometrium of adenomyosis patients in comparison with the endometrium of control patients. This was investigated through a search of the literature.
SEARCH METHODS
A systematic search was performed in PubMed and Embase until February 2019. Combinations of terms for angiogenesis and adenomyosis were applied as well as AUB, subfertility or anti-angiogenic therapy. The main search was limited to clinical studies carried out on premenopausal women. Original research articles focusing on markers of angiogenesis in the endometrium of patients with adenomyosis were included. Studies in which no comparison was made to control patients or which were not published in a peer-reviewed journal were excluded. A second search was performed to explore the therapeutic potential of targeting angiogenesis in adenomyosis. This search also included preclinical studies.
OUTCOMES
A total of 20 articles out of 1669 hits met our selection criteria. The mean vascular density (MVD) was studied by quantification of CD31, CD34, von Willebrand Factor (vWF) or factor-VIII-antibody-stained microvessels in seven studies. All these studies reported a significantly increased MVD in ectopic endometrium, and out of the six articles that took it into account, four studies reported a significantly increased MVD in eutopic endometrium compared with control endometrium. Five articles showed a significantly higher vascular endothelial growth factor expression in ectopic endometrium and three articles in eutopic endometrium compared with control endometrium. The vascular and pro-angiogenic markers α-smooth muscle actin, endoglin, S100A13, vimentin, matrix metalloproteinases (MMPs), nuclear factor (NF)-kB, tissue factor (TF), DJ-1, phosphorylated mammalian target of rapamycin, activin A, folli- and myostatin, CD41, SLIT, roundabout 1 (ROBO1), cyclooxygenase-2, lysophosphatidic acid (LPA) 1,4-5, phospho signal transducer and activator of transcription 3 (pSTAT3), interleukin (IL)-6, IL-22 and transforming growth factor-β1 were increased in ectopic endometrium, and the markers S100A13, MMP-2 and -9, TF, follistatin, myostatin, ROBO1, LPA1 and 4-5, pSTAT3, IL-6 and IL-22 were increased in eutopic endometrium, compared with control endometrium. The anti-angiogenic markers E-cadherin, eukaryotic translation initiation factor 3 subunit and gene associated with retinoic-interferon-induced mortality 19 were decreased in ectopic endometrium and IL-10 in eutopic endometrium, compared with control endometrium. The staining level of vWF and two pro-angiogenic markers (NF-κB nuclear p65 and TF) correlated with AUB in patients with adenomyosis. We found no studies that investigated the possible relationship between markers of angiogenesis and subfertility in adenomyosis patients. Nine articles reported on direct or indirect targeting of angiogenesis in adenomyosis-either by testing hormonal therapy or herbal compounds in clinical studies or by testing angiogenesis inhibitors in preclinical studies. However, there are no clinical studies on the effectiveness of such therapy for adenomyosis-related AUB or subfertility.
WIDER IMPLICATIONS
The results are in agreement with our hypothesis that increased angiogenesis is present in the endometrium of patients with adenomyosis compared with the endometrium of control patients. It is likely that increased angiogenesis leads to fragile and more permeable vessels resulting in adenomyosis-related AUB and possibly subfertility. While this association has not sufficiently been studied yet, our results encourage future studies to investigate the exact role of angiogenesis in the etiology of adenomyosis and related AUB or subfertility in women with adenomyosis in order to design curative or preventive therapeutic strategies.
Identifiants
pubmed: 31504506
pii: 5556490
doi: 10.1093/humupd/dmz024
pmc: PMC6737562
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
647-671Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.
Références
Blood. 1999 Mar 1;93(5):1612-21
pubmed: 10029590
Hum Reprod. 1999 Dec;14(12):3095-100
pubmed: 10601102
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):3884-9
pubmed: 10760260
Pharmacol Rev. 2000 Jun;52(2):237-68
pubmed: 10835101
Nat Cell Biol. 2000 Oct;2(10):737-44
pubmed: 11025665
Environ Health Perspect. 2000 Oct;108 Suppl 5:785-90
pubmed: 11035983
Hum Reprod Update. 2000 Sep-Oct;6(5):413-8
pubmed: 11045871
Mol Hum Reprod. 2001 Jan;7(1):65-72
pubmed: 11134362
Fertil Steril. 2001 Jan;75(1):131-5
pubmed: 11163827
Hum Reprod. 2001 Mar;16(3):561-6
pubmed: 11228229
Annu Rev Immunol. 2001;19:683-765
pubmed: 11244051
J Clin Endocrinol Metab. 2001 Apr;86(4):1823-34
pubmed: 11297624
Hum Reprod. 2002 Feb;17(2):265-74
pubmed: 11821262
Reproduction. 2002 Mar;123(3):379-87
pubmed: 11882015
Am J Pathol. 2002 Mar;160(3):985-1000
pubmed: 11891196
Oncogene. 2002 Mar 27;21(13):2000-8
pubmed: 11960372
Am J Reprod Immunol. 2002 Apr;47(4):242-50
pubmed: 12069391
Am J Reprod Immunol. 2002 Apr;47(4):251-5
pubmed: 12069392
Microsc Res Tech. 2003 Mar 1;60(4):445-9
pubmed: 12567401
J Natl Cancer Inst. 2003 Mar 19;95(6):437-48
pubmed: 12644537
Hum Reprod. 2003 Apr;18(4):694-9
pubmed: 12660258
Cancer Res. 2003 May 1;63(9):2322-9
pubmed: 12727857
Nat Med. 2003 Jun;9(6):653-60
pubmed: 12778163
Cancer Cell. 2003 Jul;4(1):19-29
pubmed: 12892710
Fertil Steril. 2003 Sep;80 Suppl 2:788-94
pubmed: 14505755
Int J Oncol. 2003 Nov;23(5):1317-22
pubmed: 14532971
Hum Reprod. 2004 Feb;19(2):352-6
pubmed: 14747179
J Clin Endocrinol Metab. 2004 Mar;89(3):1089-95
pubmed: 15001592
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
Pediatr Dev Pathol. 2004 Sep-Oct;7(5):468-77
pubmed: 15549611
Fertil Steril. 2005 Mar;83(3):793-5
pubmed: 15749522
Reprod Biol. 2005 Mar;5(1):51-67
pubmed: 15821778
Cancer Res. 2005 Apr 15;65(8):3193-9
pubmed: 15833850
Endocrinology. 2005 Aug;146(8):3387-400
pubmed: 15878967
Gynecol Endocrinol. 2005 Jul;21(1):57-61
pubmed: 16048803
Nature. 2005 Sep 22;437(7058):497-504
pubmed: 16177780
Angiogenesis. 2005;8(2):147-56
pubmed: 16211360
Endocrinology. 2006 Feb;147(2):724-32
pubmed: 16282351
Respir Res. 2006 Mar 02;7:37
pubmed: 16512910
Best Pract Res Clin Obstet Gynaecol. 2006 Aug;20(4):511-21
pubmed: 16563870
FASEB J. 2006 Apr;20(6):621-30
pubmed: 16581970
J Natl Cancer Inst. 2006 Jul 5;98(13):932-6
pubmed: 16818857
Gynecol Obstet Invest. 2006;62(4):229-35
pubmed: 16837781
J Leukoc Biol. 2006 Dec;80(6):1183-96
pubmed: 16997855
N Engl J Med. 2006 Oct 5;355(14):1419-31
pubmed: 17021318
Gynecol Obstet Invest. 2007;63(2):71-97
pubmed: 17028437
Oncogene. 2006 Oct 30;25(51):6680-4
pubmed: 17072321
Int J Epidemiol. 2007 Jun;36(3):666-76
pubmed: 17470488
Am J Physiol Lung Cell Mol Physiol. 2007 Sep;293(3):L557-67
pubmed: 17545484
Cancer Metastasis Rev. 2007 Dec;26(3-4):489-502
pubmed: 17717633
Cancer Sci. 2008 Mar;99(3):510-7
pubmed: 18201275
Angiogenesis. 2008;11(1):101-6
pubmed: 18283548
Ann N Y Acad Sci. 2008 Apr;1127:101-5
pubmed: 18443336
Semin Cancer Biol. 2008 Oct;18(5):349-55
pubmed: 18467122
Blood. 2008 Dec 15;112(13):4940-7
pubmed: 18515660
Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1111-6
pubmed: 19144925
N Engl J Med. 2009 Jan 15;360(3):268-79
pubmed: 19144942
Int J Gynecol Pathol. 2009 Mar;28(2):157-63
pubmed: 19188818
Int J Gynecol Pathol. 2009 Mar;28(2):148-56
pubmed: 19188819
Environ Mol Mutagen. 2009 Jun;50(5):361-6
pubmed: 19197986
Fertil Steril. 2009 Sep;92(3):886-9
pubmed: 19296948
Womens Health (Lond). 2009 May;5(3):297-311
pubmed: 19392615
Reproduction. 2009 Dec;138(6):895-902
pubmed: 19470597
Thromb Res. 2009 Sep;124(4):393-6
pubmed: 19619892
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
Arch Gynecol Obstet. 2009 Oct;280(4):529-38
pubmed: 19644696
Mol Cancer Ther. 2009 Sep;8(9):2645-54
pubmed: 19706735
Hum Reprod. 2010 Mar;25(3):642-53
pubmed: 20008888
Am J Obstet Gynecol. 2010 Apr;202(4):346.e1-8
pubmed: 20096818
Reproduction. 2010 Apr;139(4):697-704
pubmed: 20100881
Fertil Steril. 2010 Nov;94(6):1972-9, 1979.e1-4
pubmed: 20227073
Eur J Obstet Gynecol Reprod Biol. 2010 Jul;151(1):62-5
pubmed: 20409633
Hum Reprod. 2010 Jul;25(7):1806-11
pubmed: 20504870
Altern Lab Anim. 2010 May;38(2):167-82
pubmed: 20507187
Am J Hematol. 2010 Jul;85(7):487-93
pubmed: 20575035
Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5680-4
pubmed: 2062846
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Circulation. 2010 Aug 31;122(9):910-9
pubmed: 20713899
J Pathol. 2010 Nov;222(3):261-70
pubmed: 20814901
Fertil Steril. 2011 Mar 1;95(3):1164-7
pubmed: 20970134
Hum Reprod. 2011 Feb;26(2):337-45
pubmed: 21115504
Clin Cancer Res. 2011 May 15;17(10):3134-45
pubmed: 21252159
PLoS Genet. 2011 Jan 27;7(1):e1001285
pubmed: 21298084
PLoS One. 2011 Mar 21;6(3):e18074
pubmed: 21445310
Aust N Z J Obstet Gynaecol. 2011 Jun;51(3):280-3
pubmed: 21631453
Eur J Obstet Gynecol Reprod Biol. 2011 Oct;158(2):229-34
pubmed: 21664029
Eur J Radiol. 2012 Nov;81(11):3624-30
pubmed: 21719223
Eur J Obstet Gynecol Reprod Biol. 2011 Aug;157(2):206-11
pubmed: 21733615
Fertil Steril. 2011 Oct;96(4):943-50
pubmed: 21821247
BMJ Open. 2011 Feb 26;1(1):e000048
pubmed: 22021739
Hum Reprod. 2012 Jan;27(1):183-95
pubmed: 22081249
J Reprod Immunol. 2012 Jan;93(1):58-63
pubmed: 22209314
Obstet Gynecol Int. 2012;2012:786132
pubmed: 22242025
Reprod Sci. 2012 Aug;19(8):832-8
pubmed: 22477338
Mol Cell Proteomics. 2012 Jul;11(7):M112.017988
pubmed: 22493182
Hum Reprod Update. 2012 Nov-Dec;18(6):682-702
pubmed: 22718320
Fertil Steril. 2012 Sep;98(3):572-9
pubmed: 22819188
Clin Cancer Res. 2012 Nov 1;18(21):5856-64
pubmed: 23082003
Fertil Steril. 2013 Aug;100(2):568-77
pubmed: 23706331
J Midlife Health. 2013 Jan;4(1):27-30
pubmed: 23833530
Hum Reprod. 2014 May;29(5):964-77
pubmed: 24622619
Reprod Biomed Online. 2014 Jun;28(6):704-13
pubmed: 24745831
J Cell Mol Med. 2014 Jul;18(7):1358-71
pubmed: 24758741
Int J Surg. 2014 Dec;12(12):1500-24
pubmed: 25046751
Expert Opin Pharmacother. 2014 Nov;15(16):2347-60
pubmed: 25196637
Arch Gynecol Obstet. 2015 Apr;291(4):917-32
pubmed: 25241270
Int J Clin Exp Pathol. 2014 Aug 15;7(9):5762-71
pubmed: 25337217
Fertil Steril. 2015 Jan;103(1):138-46.e3
pubmed: 25455534
Biol Reprod. 2015 Feb;92(2):35
pubmed: 25505196
Biochim Biophys Acta. 2015 Apr;1855(2):155-71
pubmed: 25641676
Gynecol Obstet Invest. 2015;79(3):195-200
pubmed: 25721338
Pharmacol Rev. 2015;67(2):441-61
pubmed: 25769965
Fertil Steril. 2015 Sep;104(3):744-52.e1
pubmed: 26086422
Hum Reprod. 2015 Sep;30(9):2160-70
pubmed: 26113661
Reprod Sci. 2016 Jan;23(1):124-33
pubmed: 26239388
Hum Reprod. 2016 Feb;31(2):355-69
pubmed: 26689216
Fertil Steril. 2016 Apr;105(4):1093-101
pubmed: 26769301
Hum Reprod. 2016 Apr;31(4):734-49
pubmed: 26908845
Mol Cell Endocrinol. 2016 Jun 15;428:1-16
pubmed: 26992563
Drug Resist Updat. 2016 Mar;25:26-37
pubmed: 27155374
Am J Pathol. 2016 Aug;186(8):2129-2142
pubmed: 27315780
Gynecol Endocrinol. 2016 Sep;32(9):696-700
pubmed: 27379972
J Reprod Immunol. 2016 Nov;118:61-69
pubmed: 27665197
Reprod Biol Endocrinol. 2016 Oct 10;14(1):66
pubmed: 27724926
Gynecol Endocrinol. 2016 Oct;32(sup2):7-10
pubmed: 27759451
Angiogenesis. 2017 Feb;20(1):85-96
pubmed: 27807692
Best Pract Res Clin Obstet Gynaecol. 2017 Apr;40:68-81
pubmed: 27810281
Reprod Sci. 2017 Oct;24(10):1410-1418
pubmed: 28093048
Reprod Sci. 2017 Oct;24(10):1346-1361
pubmed: 28183227
Exp Cell Res. 2017 Apr 1;353(1):1-5
pubmed: 28257786
Angiogenesis. 2017 May;20(2):185-204
pubmed: 28361267
Angiogenesis. 2017 May;20(2):233-241
pubmed: 28389777
Reproduction. 2017 Jul;154(1):79-92
pubmed: 28495851
Cardiovasc Intervent Radiol. 2017 Sep;40(9):1344-1350
pubmed: 28516272
Acta Obstet Gynecol Scand. 2017 Jun;96(6):715-726
pubmed: 28556124
Reprod Biomed Online. 2017 Nov;35(5):592-601
pubmed: 28693952
Angiogenesis. 2018 Feb;21(1):37-46
pubmed: 28993956
J Vasc Interv Radiol. 2017 Dec;28(12):1629-1642.e1
pubmed: 29032946
BMC Womens Health. 2017 Nov 25;17(1):118
pubmed: 29178922
Exp Ther Med. 2017 Dec;14(6):6125-6130
pubmed: 29285168
Nat Commun. 2018 Jan 23;9(1):295
pubmed: 29362355
JMIR Res Protoc. 2018 Mar 01;7(3):e47
pubmed: 29496654
Fertil Steril. 2018 Mar;109(3):398-405
pubmed: 29566852
J Pharmacol Sci. 2018 May;137(1):5-11
pubmed: 29752208
Ultrasound Med Biol. 2018 Aug;44(8):1654-1663
pubmed: 29784438
Ultrasound Obstet Gynecol. 2019 May;53(5):576-582
pubmed: 29790217
Reprod Sci. 2019 Mar;26(3):377-385
pubmed: 29871559
Evid Based Complement Alternat Med. 2018 Oct 1;2018:4128984
pubmed: 30402122
Aging (Albany NY). 2019 Jan 18;11(2):328-349
pubmed: 30659163
Angiogenesis. 2019 Aug;22(3):397-410
pubmed: 30993566
Am J Obstet Gynecol. 1972 Mar;112(5):583-93
pubmed: 5059589
Nat Med. 1995 Jan;1(1):27-31
pubmed: 7584949
Gynecol Oncol. 1995 Jul;58(1):86-91
pubmed: 7789896
Am J Obstet Gynecol. 1993 Sep;169(3):734-8
pubmed: 8372890
Cancer Res. 1996 Mar 1;56(5):1111-17
pubmed: 8640769
Blood. 1996 Jul 15;88(2):667-73
pubmed: 8695814
Cell. 1996 Aug 9;86(3):353-64
pubmed: 8756718
Hum Reprod. 1996 Oct;11 Suppl 2:124-33
pubmed: 8982754
Lab Invest. 1997 Feb;76(2):267-76
pubmed: 9042163
Hum Reprod. 1998 Mar;13(3):715-9
pubmed: 9572440